Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.

对同源和异源 SARS-CoV-2 疫苗方案的免疫原性和反应原性的比较分析将为优化疫苗策略提供信息。在这里，我们在 331 名健康个体的便利队列中分析了异源和同源疫苗接种策略后的体液和细胞免疫反应。所有方案均诱导对疫苗抗原的免疫。接种 ChAdOx1-nCoV-19 后接种 BNT162b2（n  = 66）或 mRNA-1273（n = 101）后的免疫与同源 mRNA 方案（ n  = 43 BNT162b2，n  = 59 mRNA-1273  ）相当或更明显) 或同源 ChAdOx1-nCoV-19 疫苗接种 ( n = 62)。我们注意到两种异源方案后最高水平的尖峰特异性 CD8 T 细胞。在含有 mRNA 的组合中，包含 mRNA-1273 的方案中的尖峰特异性 CD4 T 细胞水平高于与 BNT162b2 的相应组合。在基于 ChAdOx1-nCoV-19 引发的方案中，多功能 T 细胞水平最高。所有五种方案都具有良好的耐受性，在 ChAdOx1-nCoV-19 引发和 ChAdOx1-nCoV-19/mRNA-1273 增强时具有最明显的反应原性。总之，我们对异源载体/mRNA 增强和同源 mRNA 方案的免疫原性和反应原性进行了比较分析。